2 weeks Ago By ABMN Staff
American Century Companies Inc. trimmed its holdings in Bio-Techne Co. ( NASDAQ:TECH – Free Report ) by 40.
5% in the second quarter, HoldingsChannel reports. The fund owned 839,110 shares of the biotechnology company’s stock after selling 570,821 shares during the period. American Century Companies Inc.
’s holdings in Bio-Techne were worth $60,122,000 at the end of the most recent quarter. A number of other hedge funds have also recently made changes to their positions in the business. First City Capital Management Inc.
lifted its holdings in shares of Bio-Techne by 6.2% in the 1st quarter. First City Capital Management Inc.
now owns 3,185 shares of the biotechnology company’s stock worth $224,000 after acquiring an additional 185 shares during the last quarter. WCM Investment Management LLC increased its stake in shares of Bio-Techne by 1.5% in the first quarter.
WCM Investment Management LLC now owns 13,220 shares of the biotechnology company’s stock worth $931,000 after buying an additional 191 shares during the period. Empirical Finance LLC increased its stake in shares of Bio-Techne by 5.2% in the first quarter.
Empirical Finance LLC now owns 3,957 shares of the biotechnology company’s stock worth $279,000 after buying an additional 195 shares during the period. Wahed Invest LLC increased its stake in shares of Bio-Techne by 9.0% in the fourth quarter.
Wahed Invest LLC now owns 2,652 shares of the biotechnology company’s stock worth $205,000 after buying an additional 220 shares during the period. Finally, Janney Montgomery Scott LLC increased its stake in shares of Bio-Techne by 2.3% in the first quarter.
Janney Montgomery Scott LLC now owns 10,164 shares of the biotechnology company’s stock worth $715,000 after buying an additional 227 shares during the period. 98.95% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets TECH has been the topic of several analyst reports. Royal Bank of Canada decreased their target price on shares of Bio-Techne from $72.00 to $70.
00 and set a “sector perform” rating on the stock in a research note on Thursday, August 8th. Citigroup downgraded shares of Bio-Techne from a “buy” rating to a “neutral” rating and set a $85.00 target price on the stock.
in a research note on Wednesday, May 22nd. Benchmark reaffirmed a “buy” rating and issued a $95.00 target price on shares of Bio-Techne in a research note on Tuesday, August 13th.
Finally, Robert W. Baird lifted their target price on shares of Bio-Techne from $81.00 to $82.
00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.
com, Bio-Techne has an average rating of “Moderate Buy” and a consensus target price of $80.60. Bio-Techne Stock Up 2.
0 % Shares of Bio-Techne stock opened at $74.67 on Monday. The company has a current ratio of 3.
87, a quick ratio of 2.75 and a debt-to-equity ratio of 0.15.
The company’s fifty day simple moving average is $74.92 and its two-hundred day simple moving average is $73.89.
The company has a market cap of $11.84 billion, a P/E ratio of 59.26, a PEG ratio of 4.
95 and a beta of 1.27. Bio-Techne Co.
has a 12-month low of $51.79 and a 12-month high of $85.57.
Bio-Techne ( NASDAQ:TECH – Get Free Report ) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.
49. The business had revenue of $306.10 million for the quarter, compared to the consensus estimate of $306.
49 million. Bio-Techne had a net margin of 14.50% and a return on equity of 12.
88%. The company’s quarterly revenue was up 1.6% compared to the same quarter last year.
During the same period in the previous year, the firm earned $0.56 EPS. Research analysts anticipate that Bio-Techne Co.
will post 1.71 EPS for the current year. Bio-Techne Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Friday, August 30th.
Stockholders of record on Monday, August 19th were given a $0.08 dividend. This represents a $0.
32 dividend on an annualized basis and a dividend yield of 0.43%. The ex-dividend date of this dividend was Monday, August 19th.
Bio-Techne’s dividend payout ratio is presently 25.40%. Bio-Techne Company Profile ( Free Report ) Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.
See Also Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Co. ( NASDAQ:TECH – Free Report ).
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter ..
